Making the Case for Arikace
TOBI or Not? Insmed Doubters Relax, $58M Raise for CF Push
By Randy Osborne
Wednesday, July 17, 2013
Investor disappointment earlier this month regarding positive but apparently not positive enough Phase III results with Insmed Inc.'s antibiotic candidate seemed to be turning around on word that the company is netting $58 million in a stock sale to help push Arikace to the finish line.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.